0. DOCID:28372 SCORE: 0.00118876643604928
DOCNO: 15989555
OWNER: NLM
STATUS: MEDLINE
AUTHOR: Michael A Morse MA
AFFILIATION: Department of Medicine, Duke University Medical Center, Durham, NC, USA. m.morse@cgct.duke.edu
PUBTYPE: Journal Article
JOURNALTITLE: Expert opinion on emerging drugs.
COUNTRY: England
TITLE: 38th Annual Meeting of the American Society of Clinical Oncology. 18-21 May 2002, Orlando, Florida, USA.
PUBDATE: 20021001
The American Society of Clinical Oncology 38th Annual Meeting has continued to showcase an increasing number of biological and targeted therapies for the treatment of cancer and its complications. This review will provide an overview of the posters and presentations describing novel biological agents.


1. DOCID:28814 SCORE: 0.00116562519851629
DOCNO: 12371585
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Sentinel Lymph Node Biopsy
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: Alex G Little AG
AFFILIATION: Department of Surgery, University of Nevada, School of Medicine, Las Vegas 89102, USA. alittle@med.unr.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Surgical clinics of North America.
COUNTRY: United States
TITLE: Sentinel node biopsy for staging lung cancer.
PUBDATE: 20020601
The importance and value of accurate clinical and pathological staging of lung cancer is emphasized. The philosophy, techniques, and general results of the sentinel node technique for lymphatic mapping are reviewed. The experience with this technique in patients with non-small cell lung cancer is discussed and the future use of lymphatic mapping is pondered.


2. DOCID:29645 SCORE: 0.00115778659645615
DOCNO: 14686738
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: immunology
QUALIFIER: blood
QUALIFIER: complications
QUALIFIER: etiology
AUTHOR: David Schiff D
AUTHOR: Josep Dalmau J
AUTHOR: Delynne J Myers DJ
AFFILIATION: Department of Neurological Surgery, University of Pittsburgh Medical Center, USA. ds4jd@virginia.edu
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Journal of neuro-oncology.
COUNTRY: Netherlands
TITLE: Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma.
PUBDATE: 20031101
Although most cases of stiff-limb syndrome are unassociated with malignancy, occasional cases have been associated with breast and lung cancer. Only four reported patients have had cancer and stiff-limb syndrome associated with anti-GAD antibodies. We report the first case of stiff-limb syndrome in a patient with multiple myeloma undergoing treatment with thalidomide, and explore the potential link to the cancer and its treatment.


3. DOCID:30318 SCORE: 0.000847456154228685
DOCNO: 16139958
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Apoptosis
QUALIFIER: physiology
QUALIFIER: physiology
QUALIFIER: physiopathology
QUALIFIER: physiology
AUTHOR: Ze-Jun Liu ZJ
AUTHOR: Xin Lu X
AUTHOR: Shan Zhong S
AFFILIATION: Laboratory of International Cooperation, Southwest Hospital, Third Military Medical University, Chongqing 400038, PRC. a65424208@cta.cq.cn
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Biochimica et biophysica acta.
COUNTRY: Netherlands
TITLE: ASPP--Apoptotic specific regulator of p53.
PUBDATE: 20050901
The p53 protein is one of the best-known tumor suppressors. The recently identified ASPP family (apoptosis-stimulating protein of p53) can interfere with the working of p53. Three members of ASPP family are proved to be apoptotic specific regulators of p53. The discovery of ASPP family may answer such questions as "how cells choose to die". Understanding the ASPP status in human cancer will allow us to develop better strategies to treat cancer.


4. DOCID:30342 SCORE: 0.000847456146674817
DOCNO: 16320132
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Andrew P Byrnes AP
AFFILIATION: Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. ByrnesA@cber.FDA.gov.
PUBTYPE: Journal Article
JOURNALTITLE: IDrugs : the investigational drugs journal.
COUNTRY: England
TITLE: Challenges and future prospects in gene therapy.
PUBDATE: 20051201
Gene therapy is a promising technique for treating disease through the modification of gene expression. It is currently being tested not only for correcting genetic defects, but also for treating cancer and other acquired diseases. Although this field is still relatively young, evidence for clinical efficacy has been observed and continued progress seems assured, as clinical trials continue to yield insights into how gene therapy can be applied and improvements are made in gene therapy tools.


5. DOCID:30279 SCORE: 0.000845997030857589
DOCNO: 14755893
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: metabolism
QUALIFIER: therapeutic use
QUALIFIER: metabolism
QUALIFIER: therapeutic use
QUALIFIER: metabolism
QUALIFIER: therapeutic use
QUALIFIER: metabolism
AUTHOR: Michael L Salgaller ML
AFFILIATION: Toucan Capital Corp, 7600 Wisconsin Ave, 7th Floor, Bethesda, MD 20814, USA. msalgaller@toucancapital.com
PUBTYPE: Evaluation Studies
PUBTYPE: Journal Article
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Technology evaluation: bevacizumab, Genentech/Roche.
PUBDATE: 20031201
Bevacizumab, an antivascular endothelial growth factor monoclonal antibody, is being developed by Genentech and Roche as an anti-angiogenesis therapy for the potential treatment of solid tumors. In June 2003, bevacizumab was granted Fast Track status by the FDA for the potential treatment of first-line colorectal cancer. The antibody is currently in phase III trials for non-small-cell lung, colorectal and breast cancers, and in phase II trials for various other solid tumor types.


6. DOCID:31449 SCORE: 0.000845883594772029
DOCNO: 12063827
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Infusions, Intra-Arterial
QUALIFIER: drug therapy
QUALIFIER: administration & dosage
QUALIFIER: drug therapy
AUTHOR: Matthias Lorenz M
AUTHOR: Stefan Heinrich S
AFFILIATION: Department of General and Vascular Surgery, University Hospital of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. M.Lorenz@em.uni-frankfurt.de
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Hematology/oncology clinics of North America.
COUNTRY: United States
TITLE: Regional chemotherapy.
PUBDATE: 20020201
Regional chemotherapy is an interesting treatment option in patients with advanced pancreatic cancer but cannot be considered standard treatment, and it should not be performed outside controlled clinical trials. The real value of regional chemotherapy must be evaluated in larger, randomized trials. New drug combinations may reduce the observed side effects and improve tumor response. Gene therapy with p53 and K-ras modulated herpesviruses may become a palliative treatment option and can be administered easily by regional chemotherapy techniques [23].


7. DOCID:28491 SCORE: 0.000845330192903122
DOCNO: 12413934
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: Nelson Gustavo Neder Kalil NG
AUTHOR: William Patrick McGuire WP
AFFILIATION: Hematology/Oncology Section, Franklin Square Hospital Center, 9000 Franklin Square Drive, Baltimore, Maryland 21237-3998, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Best practice & research. Clinical obstetrics & gynaecology.
COUNTRY: England
TITLE: Chemotherapy for advanced epithelial ovarian carcinoma.
PUBDATE: 20020801
Advanced epithelial ovarian cancer (AOC) is the most common clinical presentation of ovarian cancer. Virtually all patients will require some form of chemotherapy with curative or palliative intent. Prognostic factors, first- and second-line therapy, as well as experimental approaches for AOC are reviewed.


8. DOCID:31248 SCORE: 0.000835514993857758
DOCNO: 15868500
OWNER: NLM
STATUS: In-Process
AUTHOR: A P Zbar AP
AUTHOR: S Bernstein S
AUTHOR: N Greaves N
AUTHOR: M Iniss M
AUTHOR: R K Shenoy RK
AFFILIATION: Department of Surgery, Queen Elizabeth Hospital, University of the West Indies, Martindales Road, St. Michael, Barbados. apzbar@hotmail.com
PUBTYPE: Journal Article
JOURNALTITLE: Techniques in coloproctology.
COUNTRY: Italy
TITLE: The utilization of intraluminal formalin for intractable rectal haemorrhage in advanced rectal cancer: a case report.
PUBDATE: 20050401
A patient with a metastatic fixed low rectal carcinoma presented severe rectal bleeding requiring massive transfusion over with a 36-hour period. Bleeding was controlled with the instillation of a 4% intrarectal formalin solution permitting the completion of a course of neoadjuvant chemoradiotherapy. This technique has been reserved for intractable transfusion-dependent radiation proctitis and is presented as a primary alternative in severe rectal bleeding from inoperable rectal cancer.


9. DOCID:28056 SCORE: 0.000797152307235525
DOCNO: 13677871
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Appointments and Schedules
QUALIFIER: organization & administration
QUALIFIER: organization & administration
QUALIFIER: therapy
PUBTYPE: Journal Article
JOURNALTITLE: Performance improvement advisor.
COUNTRY: United States
TITLE: Prostate cancer clinic improves time to treatment.
PUBDATE: 20030601
Patients with prostate cancer can benefit from having alternatives to surgery, but the wide variety of options does tend to lengthen time to treatment, as patients can spend weeks going from doctor to doctor gathering information before making a decision.


10. DOCID:28768 SCORE: 0.000795837576580681
DOCNO: 12806958
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: antagonists & inhibitors
QUALIFIER: chemically induced
QUALIFIER: chemically induced
AUTHOR: Tatsuo Abe T
AUTHOR: Kenichi Nomura K
AFFILIATION: Department of Medicine, Keihoku Hospital.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: Japan
TITLE: [Second cancers associated with the cancer treatment and their possible control]
PUBDATE: 20030601
Second cancers induced by both alkylating agents and topoisomerase II inhibitors are reviewed with special reference to their distinct clinical features, incidences observed in the population at risk, cumulative risks, underlying molecular-genetic abnormalities, and also some detoxifying enzyme polymorphisms recently identified. Finally, it was discussed whether we can control these devastating diseases in the future.


11. DOCID:31084 SCORE: 0.000555464713791141
DOCNO: 15084254
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Cell Cycle Proteins
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: Julie Secombe J
AUTHOR: Sarah B Pierce SB
AUTHOR: Robert N Eisenman RN
AFFILIATION: Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cell.
COUNTRY: United States
TITLE: Myc: a weapon of mass destruction.
PUBDATE: 20040401
Growth and proliferation potentiated by deregulated myc oncogene expression is balanced by myc-induced apoptosis. Abrogation of this apoptotic pathway in Myc overexpressing cells leads to cancer progression. Recent work has shown that cell clones in the Drosophila wing disc with higher dMyc expression levels act as supercompetitors to potentiate the programmed death of surrounding normal cells. Yet another paper identifies dE2F1 as a critical component of pathways that normally restrict the ability of growth perturbing genes like dMyc to cause organ overgrowth.


12. DOCID:29622 SCORE: 0.000543898341915454
DOCNO: 14750163
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genomic Instability
DESCRIPTOR: Repressor Proteins
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: Stefan Duensing S
AUTHOR: Karl Münger K
AFFILIATION: Molecular Virology Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA. duensing@pitt.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: International journal of cancer. Journal international du cancer.
COUNTRY: United States
TITLE: Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins.
PUBDATE: 20040301
Genomic instability is a hallmark of most human cancers including high-risk human papillomavirus (HPV)-associated anogenital neoplasia. The two HPV-encoded oncoproteins, E6 and E7, can independently induce chromosomal abnormalities. We summarize the current state of knowledge concerning HPV-induced genomic instability and discuss its significance in the context of human carcinogenesis.


13. DOCID:29431 SCORE: 0.000543885595154613
DOCNO: 15123104
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Tomography, Emission-Computed
QUALIFIER: radionuclide imaging
QUALIFIER: diagnostic use
QUALIFIER: radionuclide imaging
AUTHOR: D Huglo D
AUTHOR: D Vinatier D
AFFILIATION: Service de médecine nucléaire et imagerie fonctionnelle, hôpital Claude-Huriez, CHRU de Lille.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Gynécologie, obstétrique & fertilité.
COUNTRY: France
TITLE: [Utilization of PET scan in breast and gynaecologic cancers]
PUBDATE: 20040401
The use of fluorine-18 fluorodeoxyglucose (FDG) in positron emission tomography (PET) is a major advance in imaging in the recent past. Its use in breast and gynaecologic cancers is not well established and needs to be discussed for each patient. This discussion must rely on a better knowledge of potential interests as well as of the limits of metabolic or logistic limits of PET.


14. DOCID:30288 SCORE: 0.000543883897226194
DOCNO: 12835670
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: physiology
QUALIFIER: therapy
QUALIFIER: drug therapy
QUALIFIER: drug therapy
AUTHOR: Roshan Agarwal R
AUTHOR: Stan B Kaye SB
AFFILIATION: Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK. skaye@icr.ac.uk
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Ovarian cancer: strategies for overcoming resistance to chemotherapy.
PUBDATE: 20030701
Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.